{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:16:51Z","timestamp":1787019411770,"version":"build-2736575974"},"reference-count":75,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Thyroid eye disease (TED) is an autoimmune disorder that can threaten vision loss. In 90% cases, it is related to Graves\u2019 disease, and in 10% cases, it occurs with euthyroidism or with chronic autoimmune thyroiditis. It is the leading cause of orbital pathology in adults. The TED treatment remains challenging for clinicians, particularly in moderate-to-severe or sight-threatening forms of the disease. One-third of TED patients experience a relapse despite the corticosteroids as a first-line treatment. Some patients show poor response or even no response to the treatment. There are many adverse effects associated with chronic use of intravenous methylprednisolone (IVMP). There is a need for new, efficient therapeutic methods, such as immunomodulating drugs like mycophenolate mofetil (MMF). This paper describes the role and potential efficiency of MMF application in TED by its direct action on TED pathogenic mechanisms. The introduction of MMF in the second-line treatment helps decrease the level of clinical symptoms and the risk of chronic complications, while causing only a small number of adverse events. Nevertheless, it should be noted that there are no unified guidelines available for consolidating treatment focused on maintaining remission after the first dose of IVMP. Moreover, clinical knowledge on the use of MMF application in TED is still limited, and further research is needed. Nonetheless, the available evidence is promising and MMF may play a vital role in future therapeutic strategies.<\/jats:p>","DOI":"10.1177\/20420188251383022","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:06:29Z","timestamp":1761566789000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of mycophenolate mofetil in the therapy of thyroid eye disease"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3203-8216","authenticated-orcid":false,"given":"Agnieszka","family":"Witowska","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism, and Internal Diseases, Poznan University of Medical Sciences, 49, Poland Przybyszewskiego Street, Pozna\u0144 60-355, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-1086","authenticated-orcid":false,"given":"El\u017cbieta","family":"Pawluczuk","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-3274","authenticated-orcid":false,"given":"Ewelina","family":"Szczepanek-Parulska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7220","authenticated-orcid":false,"given":"Marek","family":"Ruchala","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-1018-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.12.004"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/stresses4010004"},{"key":"e_1_3_4_5_2","unstructured":"EyeWiki. Thyroid eye disease [Internet] https:\/\/eyewiki.org\/Thyroid_Eye_Disease (2024 accessed 10 December 2024)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-014-0009-8"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S61041"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002467"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1160172"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04744-x"},{"key":"e_1_3_4_12_2","first-page":"934","article-title":"Management of hyperthyroidism using radioactive iodine\u2014current principles","author":"Jastrz\u0229bska H.","year":"2016","unstructured":"Jastrz\u0229bska H. Management of hyperthyroidism using radioactive iodine\u2014current principles. Post N Med 2016; XXIX: 934\u2013941.","journal-title":"Post N Med"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062045"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.5603\/ep.102336"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111628"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.07.007"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063288"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-024-00401-5"},{"key":"e_1_3_4_19_2","first-page":"168","article-title":"Management of Graves\u2019 ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena L","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168\u2013199.","journal-title":"Endocr Rev"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0407"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.07.24"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1614"},{"key":"e_1_3_4_23_2","unstructured":"Liaboe CA Clark TJ Shriver EM et al. Thyroid Eye Disease: An Introductory Tutorial and Overview of Disease [Internet]. EyeRounds.org. University of Iowa https:\/\/www.eyerounds.org\/tutorials\/thyroid-eye-disease\/3-TED-workup-and-diagnosis.htm (2016 accessed 25 September 2025)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-02967-9"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.145994"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2021.0017"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06716-2"},{"key":"e_1_3_4_28_2","unstructured":"Cleveland Clinic. Thyroid eye disease [Internet]. Cleveland (OH): Cleveland Clinic https:\/\/my.clevelandclinic.org\/health\/diseases\/17558-thyroid-eye-disease (2025 accessed 3 January 2025)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.94048"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.17161\/kjm.vol16.18940"},{"key":"e_1_3_4_31_2","volume-title":"Treatment of thyroid eye disease","author":"UpToDate","unstructured":"UpToDate. Treatment of thyroid eye disease [Internet]. Waltham (MA): UpToDate."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189"},{"key":"e_1_3_4_33_2","unstructured":"MedCentral. What are the appropriate steps to take when treating an individual with uncontrolled thyroid eye disease [Internet] https:\/\/www.medcentral.com\/endocrinology\/thyroid\/endo-q-what-are-the-appropriate-steps-to-take-when-treating-an-individual-with-uncontrolled-thyroid-eye-disease (accessed 10 December 2024)."},{"key":"e_1_3_4_34_2","unstructured":"Endocrine Society. Thyroid eye disease [Internet]. Endocrine Society https:\/\/www.endocrine.org\/patient-engagement\/endocrine-library\/thyroid-eye-disease (2022 accessed 10 December 2024)."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2022.0040"},{"key":"e_1_3_4_36_2","unstructured":"Manchester University NHS Foundation Trust. Thyroid eye disease (TED) patient information leaflet [Internet] https:\/\/mft.nhs.uk\/app\/uploads\/sites\/2\/2018\/04\/REH-015.pdf (2018 accessed 11 December 2024)."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab034"},{"key":"e_1_3_4_38_2","unstructured":"Oxford Academic. Thyroid eye disease: navigating the new treatment landscape [Internet] https:\/\/academic.oup.com\/jes\/article-pdf\/doi\/10.1210\/jendso\/bvab034\/41725738\/bvab034.pdf (2021 accessed 15 December 2024)."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2002.800316.x"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.5603\/ep.98913"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S193018"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac252"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S305717"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2016.04.001"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1590\/0100-6991e-20223233-en"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90078-7"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00136.x"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03082.x"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0374-8"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-023-08963-3"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.049"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-3970-y"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648732"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228456"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070776"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1079628"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0148"},{"key":"e_1_3_4_60_2","volume-title":"Tepezza (teprotumumab): EPAR\u2014public assessment report","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Tepezza (teprotumumab): EPAR\u2014public assessment report. Amsterdam: EMA, 2025."},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"e_1_3_4_63_2","unstructured":"Hornick I. Further study needed on cost-effectiveness of teprotumumab for thyroid eye disease [Internet]. Healio 21 October https:\/\/www.healio.com\/news\/ophthalmology\/20221021\/further-study-needed-on-costeffectiveness-of-teprotumumab-for-thyroid-eye-disease (2022 accessed 31 July 2025)."},{"issue":"11","key":"e_1_3_4_64_2","article-title":"Tocilizumab for thyroid eye disease","volume":"2018","author":"Hamed Azzam S","year":"2018","unstructured":"Hamed Azzam S, Kang S, Salvi M, et al. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev 2018; 2018(11): CD012984.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_65_2","unstructured":"EyeWiki. Tocilizumab for management of Graves\u2019 orbitopathy [Internet] https:\/\/eyewiki.org\/Tocilizumab_for_Management_of_Graves_Orbitopathy (2025 accessed 25 December 2024)."},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.05.007"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119845224"},{"issue":"6","key":"e_1_3_4_68_2","article-title":"Rituximab for thyroid-associated ophthalmopathy","volume":"6","author":"Kang S","year":"2022","unstructured":"Kang S, Hamed Azzam S, Minakaran N, et al. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev 2022; 6(6): CD009226.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04108-4"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0303"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1140196"},{"key":"e_1_3_4_72_2","unstructured":"Medycyna Praktyczna. Substancje lecznicze https:\/\/www.mp.pl\/pacjent\/leki\/subst.html?id=992 (n.d. accessed 3 January 2025)."},{"key":"e_1_3_4_73_2","unstructured":"Wielka Baza ChPL. Charakterystyka Produktu Leczniczego: mycophenolate mofetil alkem 500\u2009mg http:\/\/chpl.com.pl\/data_files\/2010-11-17_9_11_10__nycophenolate_mofetil_alkem_spc_pl_500_mg_clean.pdf (n.d. accessed 3 January 2024)."},{"key":"e_1_3_4_74_2","unstructured":"Mayo Clinic. Mycophenolate mofetil oral route: description https:\/\/www.mayoclinic.org\/drugs-supplements\/mycophenolate-mofetil-oral-route\/description\/drg-20073191 (2025 accessed 3 January 2025)."},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02748-w"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.788228"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251383022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188251383022","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251383022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:37:03Z","timestamp":1777592223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188251383022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"alternative-id":["10.1177\/20420188251383022"],"URL":"https:\/\/doi.org\/10.1177\/20420188251383022","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"20420188251383022"}}